Meeting
2019 Gastrointestinal Cancers Symposium
Outcomes of tyrosine kinase inhibitors (TKI) after immunotherapy in unresectable or advanced hepatocellular carcinoma (HCC) patients.
Authors
Thomas Cheung Yau
Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, Hong Kong
Thomas Cheung Yau , Vikki Tang , Jess Chan , Gin Wai Kwok , Joanne Chiu , Roland Ching-Yu Leung , Bryan Li , Tan To Cheung
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 37, 2019 (suppl 4; abstr 361)
DOI
10.1200/JCO.2019.37.4_suppl.361
Abstract #
361
Poster Bd #
K1
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Single-center real-world treatment and outcomes in patients with hepatocellular carcinoma receiving immunotherapy.
First Author: Diane Habib
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: Exploratory analysis of overall survival (OS) in the prospective, observational REFINE study.
First Author: Richard S. Finn
Poster
2020 Gastrointestinal Cancers Symposium
Immunotherapy versus biologics as second-line therapy in advanced hepatocellular carcinoma (HCC).
First Author: Mohammed Al-Jumayli
Poster
2019 Gastrointestinal Cancers Symposium
A nationwide multicenter study in patients with unresectable hepatocellular carcinoma treated with lenvatinib in real world practice in Japan.
First Author: Kaoru Tsuchiya